CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer
1998; Elsevier BV; Volume: 352; Issue: 9137 Linguagem: Inglês
10.1016/s0140-6736(05)60748-9
ISSN1474-547X
AutoresLorenz Höltl, Claudia Rieser, Christine Papesh, Reinhold Ramoner, Georg Bartsch, Martin Thurher,
Tópico(s)CAR-T cell therapy research
ResumoDendritic cells are the most potent stimulators of antigen-specific immune responses including antitumour responses. 1 Banchereau J Steinman RM Dendritic cells and the control of immunity. Nature. 1998; 392: 245-252 Crossref PubMed Scopus (12145) Google Scholar , 2 Nestle FO Alijagic S Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998; 4: 328-332 Crossref PubMed Scopus (2680) Google Scholar , 3 Murphy G Tjoa B Ragde H Kenny G Boynton A Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate. 1996; 29: 371-380 Crossref PubMed Scopus (371) Google Scholar Potent immunostimulatory dendritic cells can be isolated from peripheral blood or cultured from circulating precursor cells. 1 Banchereau J Steinman RM Dendritic cells and the control of immunity. Nature. 1998; 392: 245-252 Crossref PubMed Scopus (12145) Google Scholar , 2 Nestle FO Alijagic S Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998; 4: 328-332 Crossref PubMed Scopus (2680) Google Scholar , 3 Murphy G Tjoa B Ragde H Kenny G Boynton A Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate. 1996; 29: 371-380 Crossref PubMed Scopus (371) Google Scholar , 4 Rieser C Böck G Klocker H Bartsch G Thurnher M Prostaglandin E2 and tumor necrosis factor alpha cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production. J Exp Med. 1997; 186: 1603-1608 Crossref PubMed Scopus (233) Google Scholar The safety and efficacy of these cells is now being tested in clinical trials; data from skin, prostate, and B-lymphocyte have already been published. 1 Banchereau J Steinman RM Dendritic cells and the control of immunity. Nature. 1998; 392: 245-252 Crossref PubMed Scopus (12145) Google Scholar , 2 Nestle FO Alijagic S Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998; 4: 328-332 Crossref PubMed Scopus (2680) Google Scholar , 3 Murphy G Tjoa B Ragde H Kenny G Boynton A Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate. 1996; 29: 371-380 Crossref PubMed Scopus (371) Google Scholar
Referência(s)